人工智能辅助结肠镜用于结直肠癌筛查:一项多中心随机对照试验
这项多中心随机对照试验在香港、吉林、内蒙古、厦门和北京6家转诊中心纳入45-75岁无症状受试者3059例,随机分为人工智能辅助结肠镜组(n=1519)和常规结肠镜组(n=1540)。结果显示,人工智能辅助结肠镜组总体腺瘤检出率(39.9% vs 32.4%,P<.001)、进展期腺瘤检出率(6.6% vs 4.9%,P=.041)、专家内镜医师腺瘤检出率(42.3% vs 32.8%,P<.001)和非专家内镜医师腺瘤检出率(37.5% vs 32.1%,P=.023)以及每次结肠镜平均腺瘤数(0.59±0.97 vs 0.45±0.81,P<.001)均显著高于常规结肠镜组。
要点
- 人工智能辅助结肠镜组总体腺瘤检出率为39.9%,常规结肠镜组为32.4%(P<.001)。
- 人工智能辅助结肠镜组进展期腺瘤检出率为6.6%,常规结肠镜组为4.9%(P=.041)。
- 人工智能辅助结肠镜组中位退镜时间为8.3分钟,常规结肠镜组为7.8分钟(P=.004)。
核心结论
- 在无症状患者的多中心随机对照试验中,人工智能辅助结肠镜提高了总体腺瘤检出率、进展期腺瘤检出率以及专家和非专家主治内镜医师的腺瘤检出率。
研究设计与样本
- 多中心随机对照试验,在香港、吉林、内蒙古、厦门和北京的6家转诊中心招募45-75岁接受直接结肠镜或粪便免疫化学检测进行结直肠癌筛查的无症状受试者。
- 2019年11月至2021年8月共随机化3059例受试者,人工智能辅助结肠镜组n=1519,常规结肠镜组n=1540。
- 人工智能辅助结肠镜使用Eagle-Eye人工智能息肉检测系统,在内镜系统同一显示器上实时通知。
- 主要结局为总体腺瘤检出率;次要结局为每次结肠镜平均腺瘤数、按内镜医师经验分层的腺瘤检出率和结肠镜退镜时间。
主要发现
- 总体腺瘤检出率人工智能辅助结肠镜组为39.9%,常规结肠镜组为32.4%(P<.001)。
- 进展期腺瘤检出率人工智能辅助结肠镜组为6.6%,常规结肠镜组为4.9%(P=.041)。
- 专家内镜医师腺瘤检出率人工智能辅助结肠镜组为42.3%,常规结肠镜组为32.8%(P<.001)。
- 非专家内镜医师腺瘤检出率人工智能辅助结肠镜组为37.5%,常规结肠镜组为32.1%(P=.023)。
- 每次结肠镜平均腺瘤数人工智能辅助结肠镜组为0.59±0.97,常规结肠镜组为0.45±0.81(P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Artificial intelligence (AI)-assisted colonoscopy improves polyp detection and characterization in colonoscopy. However, data from large-scale multicenter randomized controlled trials (RCT) in an asymptomatic population are lacking. METHODS: This multicenter RCT aimed to compare AI-assisted colonoscopy with conventional colonoscopy for adenoma detection in an asymptomatic population. Asymptomatic subjects 45-75 years of age undergoing colorectal cancer screening by direct colonoscopy or fecal immunochemical test were recruited in 6 referral centers in Hong Kong, Jilin, Inner Mongolia, Xiamen, and Beijing. In the AI-assisted colonoscopy, an AI polyp detection system (Eagle-Eye) with real-time notification on the same monitor of the endoscopy system was used. The primary outcome was overall adenoma detection rate (ADR). Secondary outcomes were mean number of adenomas per colonoscopy, ADR according to endoscopist's experience, and colonoscopy withdrawal time. This study received Institutional Review Board approval (CRE-2019.393). RESULTS: From November 2019 to August 2021, 3059 subjects were randomized to AI-assisted colonoscopy (n = 1519) and conventional colonoscopy (n = 1540). Baseline characteristics and bowel preparation quality between the 2 groups were similar. The overall ADR (39.9% vs 32.4%; P < .001), advanced ADR (6.6% vs 4.9%; P = .041), ADR of expert (42.3% vs 32.8%; P < .001) and nonexpert endoscopists (37.5% vs 32.1%; P = .023), and adenomas per colonoscopy (0.59 ± 0.97 vs 0.45 ± 0.81; P < .001) were all significantly higher in the AI-assisted colonoscopy. The median withdrawal time (8.3 minutes vs 7.8 minutes; P = .004) was slightly longer in the AI-assisted colonoscopy group. CONCLUSIONS: In this multicenter RCT in asymptomatic patients, AI-assisted colonoscopy improved overall ADR, advanced ADR, and ADR of both expert and nonexpert attending endoscopists. (ClinicalTrials.gov, Number: NCT04422548).
引用
- Xu H, Tang RSY, Lam TYT, et al. Artificial Intelligence-Assisted Colonoscopy for Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2022. PMID: 35863686. doi:10.1016/j.cgh.2022.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。